These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 23257024)
1. Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction. Huang BS; Ahmad M; White RA; Marc Y; Llorens-Cortes C; Leenen FH Cardiovasc Res; 2013 Mar; 97(3):424-31. PubMed ID: 23257024 [TBL] [Abstract][Full Text] [Related]
2. Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. Leenen FHH; Ahmad M; Marc Y; Llorens-Cortes C J Cardiovasc Pharmacol; 2019 Feb; 73(2):82-91. PubMed ID: 30531435 [TBL] [Abstract][Full Text] [Related]
3. Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction. Huang BS; White RA; Ahmad M; Tan J; Jeng AY; Leenen FH Cardiovasc Res; 2009 Feb; 81(3):574-81. PubMed ID: 18689429 [TBL] [Abstract][Full Text] [Related]
4. Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice. Boitard SE; Marc Y; Keck M; Mougenot N; Agbulut O; Balavoine F; Llorens-Cortes C J Mol Cell Cardiol; 2019 Feb; 127():215-222. PubMed ID: 30599150 [TBL] [Abstract][Full Text] [Related]
5. Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction. Zhang W; Huang BS; Leenen FH Am J Physiol; 1999 May; 276(5):H1608-15. PubMed ID: 10330245 [TBL] [Abstract][Full Text] [Related]
6. Sympathetic hyperactivity and cardiac dysfunction post-MI: different impact of specific CNS versus general AT1 receptor blockade. Huang BS; Ahmad M; Tan J; Leenen FH J Mol Cell Cardiol; 2007 Oct; 43(4):479-86. PubMed ID: 17714732 [TBL] [Abstract][Full Text] [Related]
7. Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen. Wang H; Huang BS; Ganten D; Leenen FH Circ Res; 2004 Apr; 94(6):843. PubMed ID: 15061159 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors, inhibition of brain and peripheral angiotensin-converting enzymes, and left ventricular dysfunction in rats after myocardial infarction. Ahmad M; White R; Tan J; Huang BS; Leenen FH J Cardiovasc Pharmacol; 2008 Jun; 51(6):565-72. PubMed ID: 18496146 [TBL] [Abstract][Full Text] [Related]
9. Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats post-myocardial infarction. Huang BS; Ahmad M; Tan J; Leenen FH Am J Physiol Heart Circ Physiol; 2009 Sep; 297(3):H968-75. PubMed ID: 19617416 [TBL] [Abstract][Full Text] [Related]
10. Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. Marc Y; Gao J; Balavoine F; Michaud A; Roques BP; Llorens-Cortes C Hypertension; 2012 Aug; 60(2):411-8. PubMed ID: 22710644 [TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid and AT1 receptors in the paraventricular nucleus contribute to sympathetic hyperactivity and cardiac dysfunction in rats post myocardial infarct. Huang BS; Chen A; Ahmad M; Wang HW; Leenen FH J Physiol; 2014 Aug; 592(15):3273-86. PubMed ID: 24951624 [TBL] [Abstract][Full Text] [Related]
12. Brain ACE2 activation following brain aminopeptidase A blockade by firibastat in salt-dependent hypertension. Hmazzou R; Marc Y; Flahault A; Gerbier R; De Mota N; Llorens-Cortes C Clin Sci (Lond); 2021 Mar; 135(6):775-791. PubMed ID: 33683322 [TBL] [Abstract][Full Text] [Related]
13. Brain renin-angiotensin system and ouabain-induced sympathetic hyperactivity and hypertension in Wistar rats. Huang BS; Leenen FH Hypertension; 1999 Jul; 34(1):107-12. PubMed ID: 10406832 [TBL] [Abstract][Full Text] [Related]
14. Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI. Huang BS; Leenen FH Am J Physiol Heart Circ Physiol; 2005 May; 288(5):H2491-7. PubMed ID: 15615845 [TBL] [Abstract][Full Text] [Related]
15. Targeting Brain Aminopeptidase A: A New Strategy for the Treatment of Hypertension and Heart Failure. Marc Y; Boitard SE; Balavoine F; Azizi M; Llorens-Cortes C Can J Cardiol; 2020 May; 36(5):721-731. PubMed ID: 32389345 [TBL] [Abstract][Full Text] [Related]
16. Brain "ouabain" and angiotensin II contribute to cardiac dysfunction after myocardial infarction. Leenen FH; Yuan B; Huang BS Am J Physiol; 1999 Nov; 277(5):H1786-92. PubMed ID: 10564131 [TBL] [Abstract][Full Text] [Related]
17. The role of the brain renin-angiotensin system in hypertension: implications for new treatment. Marc Y; Llorens-Cortes C Prog Neurobiol; 2011 Oct; 95(2):89-103. PubMed ID: 21763394 [TBL] [Abstract][Full Text] [Related]
18. Possible mechanism by which renal sympathetic denervation improves left ventricular remodelling after myocardial infarction. Zheng XX; Li XY; Lyu YN; He YY; Wan WG; Zhu HL; Jiang XJ Exp Physiol; 2016 Feb; 101(2):260-71. PubMed ID: 26556551 [TBL] [Abstract][Full Text] [Related]
19. Central TrkB blockade attenuates ICV angiotensin II-hypertension and sympathetic nerve activity in male Sprague-Dawley rats. Becker BK; Wang H; Zucker IH Auton Neurosci; 2017 Jul; 205():77-86. PubMed ID: 28549782 [TBL] [Abstract][Full Text] [Related]
20. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Bodineau L; Frugière A; Marc Y; Inguimbert N; Fassot C; Balavoine F; Roques B; Llorens-Cortes C Hypertension; 2008 May; 51(5):1318-25. PubMed ID: 18362226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]